Publication:
Heart rate dynamics in doxorubicin-induced cardiomyopathy

Simple item page
dc.contributor.authorLončar-Turukalo, T. (24478354200)
dc.contributor.authorVasić, M. (56277862600)
dc.contributor.authorTasić, T. (56394333000)
dc.contributor.authorMijatović, G. (55513889700)
dc.contributor.authorGlumac, S. (33467624700)
dc.contributor.authorBajić, D. (56186463400)
dc.contributor.authorJapunžić-Žigon, N. (56572866800)
dc.date.accessioned2025-07-02T12:28:46Z
dc.date.available2025-07-02T12:28:46Z
dc.date.issued2015
dc.description.abstractThe clinical use of doxorubicin, an effective chemotherapeutic is hampered by the development of irreversible cardiotoxicity. Here we test time-frequency analysis of heart rate (HR) variability (HRV) for early detection of doxorubicin-induced cardiotoxicity. Experiments were conducted in adult male Wistar rats treated for 15 days with doxorubicin (DOXO, total dose 15 mg kg-1, i.p.) or saline (CONT). DOXO rats exhibited cardiotoxicity confirmed by histological examination without developing heart failure as estimated by echocardiography. However, HR variability increase reflected subtle microscopic changes of cardiac toxicity in DOXO rats. The results recommend time-frequency analysis of HRV for early detection of doxorubicin-induced cardiomyopathy. © 2015 Institute of Physics and Engineering in Medicine.
dc.identifier.urihttps://doi.org/10.1088/0967-3334/36/4/727
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84925686118&doi=10.1088%2f0967-3334%2f36%2f4%2f727&partnerID=40&md5=5f734c257b93bef69a9562d623c08908
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/13530
dc.subject37M10 time series analysis
dc.subjectcardiotoxicity
dc.subjectdoxorubicin
dc.subjectheart rate variability
dc.subjectHilbertHuang transform
dc.subjectMSC 92C30 physiology
dc.titleHeart rate dynamics in doxorubicin-induced cardiomyopathy
dspace.entity.typePublication

Files

Collections

Publikacije / Publications